treats Hepatitis, Arthritis, Respiratory disease, HIV, Immunomodulation, and Cancer
This information is based on a systematic review of scientific literature, and was peer- reviewed and edited by contributors to the Natural Standard Research Collaboration (www.naturalstandard.com): Ethan Basch, MD (Memorial Sloan- Kettering Cancer Center); Julie Conquer (RGB Consulting); Dawn Costa, BA, BS (Natural Standard Research Collaboration); Raquel Domínguez, MD (Natural Standard Research Collaboration); Nicole Giese, MS (Natural Standard Research Collaboration); Dana A. Hackman, BS (Northeastern University); Michael Heller, PhD (Harvard School of Public Health); Andy Joseph, PharmD (Massachusetts College of Pharmacy); Nikos Linardakis, MD (Natural Standard Research Collaboration); Mary McGarry, RPh. (University of Rhode Island); Susanne Schadde, MD (Natural Standard Research Collaboration); Lisa Scully, PharmD (Massachusetts College of Pharmacy); Erica Seamon (Nova Southeastern University); Shaina Tanguay- Colucci, BS (Natural Standard Research Collaboration); Catherine Ulbricht, PharmD (Massachusetts General Hospital); Wendy Weissner, BA (Natural Standard Research Collaboration); Jen Woods, BS (Natural Standard Research Collaboration).
BibliographyDISCLAIMER: Natural Standard developed the above evidence- based information based on a thorough systematic review of the available scientific articles. For comprehensive information about alternative and complementary therapies on the professional level, go to www.naturalstandard.com. Selected references are listed below.
Bar- Sela G, Gershony A, Haim N. Mistletoe (Viscum album) preparations: an optional drug for cancer patients? Harefuah 2006 Jan;145(1):42- 6, 77.
Bock PR, Friedel WE, Hanisch J, et al. [Efficacy and safety of long- term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non- metastasized mammary carcinoma. Results of a multi- center, comparative, epidemiological cohort study in Germany and Switzerland]. Arzneimittelforschung 2004;54(8):456- 466.
Elsasser- Beile U, Leiber C, et al. Adjuvant intravesical treatment with a standardized mistletoe extract to prevent recurrence of superficial urinary bladder cancer. Anticancer Res 2005 Nov- Dec;25(6C):4733- 6.
Finall AI, McIntosh SA, Thompson WD. Subcutaneous inflammation mimicking metastatic malignancy induced by injection of mistletoe extract. BMJ 2006 Dec 23;333(7582):1293- 4.
Grossarth- Maticek R, Ziegler R. Prospective controlled cohort studies on long- term therapy of breast cancer patients with a mistletoe preparation (Iscador). Forsch Komplement Med 2006 Oct;13(5):285- 92.
Grossarth- Maticek R, Ziegler R. Prospective controlled cohort studies on long- term therapy of cervical cancer patients with a mistletoe preparation (Iscador). Forsch Komplement Med 2007 Jun;14(3):140- 7.
Grossarth- Maticek R, Ziegler R. Randomised and non- randomised prospective controlled cohort studies in matched- pair design for the long- term therapy of breast cancer patients with a mistletoe preparation (Iscador): a re- analysis. Eur J Med Res 2006 Nov 30;11(11):485- 95.
Huber R, Classen K, Werner M, et al. In vitro immunoreactivity towards lectin- rich or viscotoxin- rich mistletoe (Viscum album L.) extracts Iscador applied to healthy individuals. Arzneimittelforschung 2006 Jun;56(6A):447- 56.
Huber R, Rostock M, Goedl R, et al. Immunologic effects of mistletoe lectins: a placebo- controlled study in healthy subjects. J Soc Integr Oncol 2006 Winter;4(1):3- 7.
Kirsch A. Successful treatment of metastatic malignant melanoma with Viscum album extract (Iscador M). J Altern Complement Med 2007 May;13(4):443- 5.
Piao BK, Wang YX, Xie GR, et al. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non- small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res 2004;24(1):303- 309.
Schink M, Troger W, Dabidian A, et al. Mistletoe extract reduces the surgical suppression of natural killer cell activity in cancer patients. a randomized phase III trial. Forsch Komplement Med (2006). 2007 Feb;14(1):9- 17.
Schumacher K, Schneider B, Reich G, et al. Influence of postoperative complementary treatment with lectin- standardized mistletoe extract on breast cancer patients. A controlled epidemiological multicentric retrolective cohort study. Anticancer Res 2003;23(6D):5081- 5087.
Seifert G, Tautz C, Seeger K, et al. Therapeutic use of mistletoe for CD30+ cutaneous lymphoproliferative disorder/ lymphomatoid papulosis. J Eur Acad Dermatol Venereol. 2007 Apr;21(4):558- 60.
Semiglazov VF, Stepula VV, Dudov A, et al. Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow- up: a randomised, placebo- controlled, double- blind, multicentre clinical trial. Anticancer Res 2006 Mar- Apr;26(2B):1519- 29.
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.